Table 1.

Baseline demographic and clinical features.

Demographic and clinical features of treatment groups at baseline. Group 1 received CoQ10 supplementation along with IFN-β1a over the first 3 months, followed by IFN-β1a alone for 3 months; Group 2 received IFN-β1a alone over the first 3 months, followed by CoQ10 supplementation along with IFN-β1a for 3 months. p values are reported from a Chi-square test, Fisher’s exact test or Student’s t test.

	Group 1 (n = 30)	Group 2 (n = 30)	p values
Age, years	42.1 ± 10.5	40.9 ± 9.0	0.639
Sex, female (%)	21 (70%)	21 (70%)	0.999
Disease duration, years	10.9 ± 2.0	11.1 ± 1.5	0.662
Baseline EDSS	2.7 ± 1.0	2.6 ± 1.0	0.943
Naïve patients, number (%)	15 (50%)	15 (50%)	0.999
Duration of IFN-β1a, years	5.2 ± 4.2	4.5 ± 4.7	0.912

CoQ10, coenzyme Q10; EDSS, Expanded Disability Status Scale; IFN-β1a, interferon-beta1a 44μg.